NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Clinical trials for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Gene-Based bladder cancer treatment shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called EG-70 (detalimogene) for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The drug is given directly into the bladder through a catheter. The trial includes patients whose cancer did not respond to standard BCG therapy…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE1, PHASE2 • Sponsor: enGene, Inc. • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
Gene therapy combo offers new hope for tough bladder cancer
Disease control Recruiting nowThis phase 3 trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemotherapy or immunotherapy. It is for people with a type of bladder cancer (non-muscle invasive) that has not responded to standard BCG therapy. The s…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC